Have a personal or library account? Click to login
Yes, MAM: how the cancer-related EMP3 protein became a regulator of erythropoiesis and the key protein underlying a new blood group system Cover

Yes, MAM: how the cancer-related EMP3 protein became a regulator of erythropoiesis and the key protein underlying a new blood group system

Immunohematology
Volume 38 (2022): Issue 4 (December 2022)
By: M.D. Ilsley,  J.R. Storry and  M.L. Olsson  
Open Access
|Dec 2022

Authors

M.D. Ilsley

Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden

J.R. Storry

Experimental Transfusion Medicine, Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Technical Director, Immunohematology, Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund

M.L. Olsson

martin_l.olsson@med.lu.se

Transfusion Medicine, Deputy Dean, Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Medical Director of the Nordic Reference Laboratory for Genomic Blood Group Typing, Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Lund
DOI: https://doi.org/10.21307/immunohematology-2022-055 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Journal RSS Feed
Language: English
Page range: 130 - 136
Published on: Dec 28, 2022
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
MAM,
EMP3,
blood group,
high-prevalence antigen
Related subjects:
Medicine,
Clinical medicine,
Laboratory medicine

© 2022 M.D. Ilsley, J.R. Storry, M.L. Olsson, published by American National Red Cross
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 38 (2022): Issue 4 (December 2022)Next article